• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Oppenheimer John J.

    9/25/25 5:16:54 PM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $BIAF alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Oppenheimer John J.

    (Last) (First) (Middle)
    C/O BIOAFFINITY TECHNOLOGIES, INC.,
    3300 NACOGDOCHES ROAD, SUITE 216

    (Street)
    SAN ANTONIO, TX 78217

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    08/12/2025
    3. Issuer Name and Ticker or Trading Symbol
    bioAffinity Technologies, Inc. [ BIAF ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ John J. Oppenheimer 09/25/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BIAF alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIAF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIAF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Rios Roberto claimed ownership of 833 shares (SEC Form 3)

    3 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

    9/25/25 5:19:36 PM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 3 filed by new insider Oppenheimer John J.

    3 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

    9/25/25 5:16:54 PM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Operating Officer Reveles Xavier Trinidad was granted 21,604 shares, increasing direct ownership by 106% to 41,943 units (SEC Form 4)

    4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

    1/14/25 4:15:26 PM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BIAF
    SEC Filings

    View All

    SEC Form EFFECT filed by bioAffinity Technologies Inc.

    EFFECT - bioAffinity Technologies, Inc. (0001712762) (Filer)

    9/30/25 12:15:23 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form S-1/A filed by bioAffinity Technologies Inc.

    S-1/A - bioAffinity Technologies, Inc. (0001712762) (Filer)

    9/25/25 9:29:45 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form S-1 filed by bioAffinity Technologies Inc.

    S-1 - bioAffinity Technologies, Inc. (0001712762) (Filer)

    9/24/25 8:30:53 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BIAF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m

    JERSEY CITY, N.J., Sept. 29, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer has priced a public offering of securities as described below for aggregate gross proceeds to the Company of $ million, before deducting agent fees and other estimated expenses payable by the company. The offering consists of 1,921,799 shares (the "Shares") o

    9/29/25 5:59:00 PM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering

    bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has priced a public offering of securities as described below for aggregate gross proceeds to the Company of $4.8 million, before deducting agent fees and other estimated expenses payable by the company. The offering consists of 1,921,799 shares (the "Shares") of our Common Stock (or pre-funded warrants (the "Pre-Funded Warrants") in lieu thereof) at a purchase price of $2.50 per share (or $2.493 per Pre-Funded Warrant). Each Pre-Funded Warrant will be exercisable for one share of our Common Stock and will b

    9/29/25 3:51:00 PM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung

    Noninvasive diagnostic test again leads to detecting Stage 1A lung cancer bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released three additional case studies – one in which use of CyPath® Lung led to detecting lung cancer at Stage 1A, its earliest and possibly curative stage, and two where risky invasive procedures were avoided for patients facing difficult healthcare choices. "These three new cases, provided by a Texas pulmonologist who has been using CyPath® Lung for more than a year, reflect what we're hearing from many physicians – CyPath® Lung enhances clinical decision

    9/26/25 8:00:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BIAF
    Leadership Updates

    Live Leadership Updates

    View All

    bioAffinity Technologies Appoints New Members to Board of Directors

    Financial and Clinical Leaders Provide Significant Expertise for the Company's Commercial Growth bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing noninvasive diagnostics for the early detection of lung cancer and other diseases, today announced the appointment of Roberto Rios, CPA, and John J. Oppenheimer, M.D., to its Board of Directors. "Mr. Rios' business and financial expertise combined with Dr. Oppenheimer's clinical leadership will be invaluable as we increase sales of CyPath® Lung, develop companion diagnostics for asthma and COPD, and strengthen our financial position," said Maria Zannes, President and CEO of bioAffinity Technologies. Mr.

    8/18/25 8:00:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

    bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other diseases of the lung, today announced that its President and CEO, Maria Zannes, has been selected to serve on the American Lung Association in Texas' Leadership Board, a distinguished group of healthcare professionals and advocates committed to advancing lung health. As a member of the Texas Leadership Board, Ms. Zannes will play an important role in supporting the Lung Association's mission to improve lives by preventing lung disease and promoting lung health through research, education and advocacy. Board

    6/11/25 9:00:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

    bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as its new Chief Medical Officer (CMO). Dr. Downie brings more than three decades of experience in pulmonary medicine, clinical research, medical innovation, and interventional pulmonology to the role. Dr. Downie has authored more than 30 peer-reviewed publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development. He has worked extensively in both academic medicine and private practice, led FDA-approved resea

    5/20/25 9:00:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BIAF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by bioAffinity Technologies Inc.

    SC 13G - bioAffinity Technologies, Inc. (0001712762) (Subject)

    10/10/23 6:03:06 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BIAF
    Financials

    Live finance-specific insights

    View All

    Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ENLV: https://www.redchip.com/assets/access/enlv_accessBIAF: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a c

    1/10/25 9:00:00 AM ET
    $BIAF
    $ENLV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (NASDAQ:BTCY) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Biotricity: https://www.redchip.com/assets/access/btcy_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity, will share insight into the company's innovative portfolio of car

    7/12/24 9:35:00 AM ET
    $BIAF
    $BTCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Medical/Dental Instruments

    BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs target

    7/5/24 9:00:00 AM ET
    $BIAF
    $BIVI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations